Compare · JSPR vs MRNA
JSPR vs MRNA
Side-by-side comparison of Jasper Therapeutics Inc. (JSPR) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JSPR and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.41B, about 2646.0x JSPR ($24.0M).
- Over the past year, JSPR is down 75.6% and MRNA is up 541.9% - MRNA leads by 617.5 points.
- Both names hit the wire about 10 times in the past 4 weeks.
- MRNA has more recent analyst coverage (25 ratings vs 24 for JSPR).
- Company
- Jasper Therapeutics Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $24.0M
- $63.41B
- 1M return
- +4.16%
- +185.74%
- 1Y return
- -75.56%
- +541.94%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 10
- 10
- Recent ratings
- 24
- 25
Jasper Therapeutics Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest JSPR
- SEC Form PRE 14A filed by Jasper Therapeutics Inc.
- SEC Form 10-Q filed by Jasper Therapeutics Inc.
- Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Piper Sandler initiated coverage on Jasper Therapeutics with a new price target
- SEC Form 4 filed by Director Wiggans Thomas G
- SEC Form 4 filed by Director Emster Kurt Von
- SEC Form 4 filed by Director Lucas Svetlana
- SEC Form 4 filed by Director Crutcher Patrick J
- SEC Form 4 filed by Director Shizuru Judith Anne
- Jasper Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest MRNA
- Moderna upgraded by Wolfe Research
- Moderna upgraded by BofA Securities
- Moderna upgraded by William Blair
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.
- Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus